anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To prolong the life and provide longevity, by transplanting young juvenile internal organs.viscera.tissues, etc., of a youth into the body of an aged man. CONSTITUTION:Young internal organs.viscera.tissues, etc., of a youth, e.g. a man of zero-30 years old or fetus, are transplanted into the body of an aged man. In the process, the blood type and histocompatibility of both are carefully preexamined and only compatible or internal organs, etc., are transplanted to prevent rejection in any case. An immunosuppressive agent, if necessary, is used. Considerations are given as follows. The immunosuppressive agent is prevented from extending to the whole body and limited action is exerted only on transplanted parts and peripheries thereof. Secretion is carried out in a very small amount by the required minimum amount for a long period. Furthermore, if monogenetic cells of the aged man are cultivated and whole cultivation is carried out for a long period after development and differentiation of the respective organs, internal organs, etc., are separated and cultivated to transplant grown cells of sufficient size, there is no fear of rejection. The above-mentioned transplanting is performed to prolong the life and provide longevity.
Virion-associated peptidoglycan hydrolases have a potential as antimicrobial agents due to their ability to lyse Gram positive bacteria on contact. Full-length HydH5, a virion-associated peptidoglycan hydrolase from the  Staphylococcus aureus  bacteriophage vB_SauS-phi-IPLA88, and two truncated derivatives, containing only the CHAP domain, exhibited high lytic activity against live  S. aureus  cells. Three different fusion proteins were created and showed higher staphylolytic activity than the parental enzyme or its deletion construct. Parental and fusion proteins lysed  S. aureus  cells in zymograms, plate lysis and turbidity reduction assays. In plate lysis assays, HydH5 and its derivative fusions lysed bovine and human  S. aureus, S. aureus  MRSA N315 strain, and human  Staphylococcus epidermidis  strains. HydH5 and its derivative fusions proteins displayed antimicrobial synergy with the endolysin LysH5 in vitro suggesting that the two enzymes have distinct cut sites and thus may be more efficient in combination for the elimination of staphylococcal infections.
Aggressive treatment for patients with out-of-hospital cardiac arrest (OHCA) can result in return of spontaneous circulation (ROSC). However, prognosis for these patients remains poor, with low rates of survival to hospital admission and low rates of survival to hospital discharge. Furthermore, due to the exquisite sensitivity to hypoxic injury of neural tissue (dependent on aerobic respiration) relative to that of cardiac muscle, patients for whom ROSC can be obtained often suffer devastating neurological injury, with potential poor long-term neurological outcome. In some ischemic processes, for example, myocardial infarction, rapid measurement of cardiac biomarkers (e.g. Troponin isoform) is invaluable to current diagnosis and management. However, with regards to ischemic brain injury, there is currently no rapid, definitive diagnostic test to prognosticate outcome in OHCA. Biomarkers measurable in blood would have vital applications in prognosis and clinical research of neurological outcome in OHCA.

Other groups have studied the neurological predictive values of biomarkers after OHCA. A variety of proteins including S100B, neuron-specific enolase, and G-FAP, co-peptin, Tau, neurofilament light/ heavy chain, and secretoneurin have been proposed as potential biomarkers of neurological outcome at OHCA. Unfortunately, many of these have been shown to have several drawbacks. For example, some lack specificity due to being released during resuscitation (e.g., S100B is found extracerebrally in muscle, adipocytes, and chondrocytes, creating a confounding factor in CA patients receiving chest compressions). Others have lacked sufficient sensitivity in the prognosticating of neurological outcome (ref). Furthermore, there is a paucity of human studies in cardiac arrest on newer biomarkers that have been studied in other acute brain injury disease processes that could potentially serve as candidate biomarkers predicting neurological outcome at post cardiac arrest hypoxic brain injuries. Biomarkers such as UCH-L1, SBDP, and MBP have not been studied in a OHCA cohort.

The Investigator therefore propose a prospective, observational study in which the investigator will incorporate a minimally invasive and minimal risk measurement of blood biomarkers at time of ROSC. This would be done by drawing blood at ROSC (0-59mins), and additional blood draws at hours 6, 12, 18, 24, 48, 72, and on day 4, 5, and 6. The Investigator will then determine whether biomarker levels correlates with survival to hospital admission, survival to hospital discharge, and functional neurologic outcome at discharge and at 6 months. The Investigator intend to sample patients that present to the emergency department with non-CA chest pain in our study as well, which will allow us to draw stable inferences.
PROBLEM TO BE SOLVED: To provide the subject new gene composed of a gene coding for a hepatocyte proliferation factor, having a specific amino acid sequence and usable e.g. for the production of the proliferation factor useful as a liver regeneration promoter, liver function improver, hepatitis treating agent, hepatocirrhosis suppressing agent, etc. SOLUTION: This new gene coding for a hepatocyte proliferation factor is expressed by the sequence from the 30th glutamic acid to the 728th serine of the amino acid sequence expressed by the formula. The gene is useful e.g. for the production of a hepatocyte proliferation factor having possibility to be usable as a hepatic disease treating agent such as a liver regeneration promoter, a liver function improver, a hepatitis treating agent, a hepatocirrhosis suppressing agent, etc. The gene can be produced by screening a λ-phage cDNA library originated from human placenta by plaque hybridization method using a probe consisting of an oligonucleotide produced from a base sequence estimated from an amino acid sequence constituting a part of the hepatocyte proliferation factor.
The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury. The primary outcomes of interest in the proposed trial are injury recidivism, alcohol intake, and alcohol problems. Because brief alcohol interventions with injured patients are opportunistic in nature, the patient's motivation to change or stage of change likely influences their response to brief intervention as well as the need for additional intervention. Therefore, the primary hypothesis of the proposed research is that patients presenting for treatment of an alcohol related injury who are in the precontemplation or contemplation stages of change require brief intervention with booster while patients in the preparation or action stages of change benefit equally from brief intervention alone or brief intervention plus booster. That is, an interaction between the patient's stage of change (Precontemplation and Contemplation or Action) at enrollment and treatment type (Brief Intervention, Brief Intervention with Booster and Treatment as Usual) is hypothesized to influence treatment effect at follow up. In addition, the impact of intervention on the patient's motivation to change at follow up will be assessed.
We present a fatal complication of treatment in a patient with early-onset acromegaly, treated with two transsphenoidal operations, radiotherapy, radiosurgery and pegvisomant. He was diagnosed in his 30s, and controlled from his 40s, with stable residual tumour within the left cavernous sinus. In his 60s, 30 years after surgery/radiotherapy and 14 years after radiosurgery, he developed recurrent episodes of mild epistaxis. A week later, he presented at his local hospital's emergency department with severe epistaxis and altered consciousness. He was diagnosed with a ruptured internal carotid artery (ICA) pseudoaneurysm, but unfortunately died before treatment could be attempted.ICA pseudoaneurysms are rare complications of surgery or radiotherapy and can present with several years of delay, often with epistaxis. This case highlights the importance of life-long monitoring in patients with previous pituitary interventions and early recognition of epistaxis as a herald sign of a potentially catastrophic event, thus leading to timely treatment.
Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy (or at RBE ("Relative Biologic Equivalence" for PBT)) to be delivered to the periphery of the planning target volume (PTV).
[00112] Disclosed is a three-phase emulsion comprising an aqueous-gel outer phase; and a water-in-oil inner phase, wherein the emulsion is stable. The aqueous-gel outer phase can include 10% to 50% by weight of the total weight of the emulsion. This phase can also include 70% to 95% by weight of water based on the total weight of the aqueous-gel outer phase, a gelling agent, and an emulsifÏer having a hydrophilic-lipophilic balance (HLB) value of 10 to 19. The water-in-oil inner phase can include 50% to 95% by weight based on the total weight of the three-phase emulsion. This phase can also include 50% to 80% by weight of water based on the total weight of the water-in-oil inner phase, 20% to 50% by weight of oil based on the total weight of the water-in-oil inner phase, and an emulsifier. [00112] Disclosed is a three-phase emulsion comprising an aqueous-gel outer phase; and a water-in-oil inner phase, wherein the emulsion is stable. The aqueous-gel outer phase can include 10% to 50% by weight of the total weight of the emulsion. This phase can also include 70% to 95% by weight of water based on the total weight of the aqueous-gel outer phase, a gelling agent, and an emulsifÏer having a hydrophilic-lipophilic balance (HLB) value of 10 to 19. The water-in-oil inner phase can include 50% to 95% by weight based on the total weight of the three-phase emulsion. This phase can also include 50% to 80% by weight of water based on the total weight of the water-in-oil inner phase, 20% to 50% by weight of oil based on the total weight of the water-in-oil inner phase, and an emulsifier. An acoustic baffle assembly for sealing or baffling a hollow body having a mass of heat activated expandable material that is capable of activating at a predetermined temperature. A substrate supports the mass. The substrate has a central portion and spaced apart projections extending outwardly from the central portion. The projections are configured to control expansion of the mass.
Arm B for resectable malignant glioma completed the Phase I accrual and long term follow up continues. A follow on study at dose level 3 was opened as a Phase 2a study (see BrTK02).
OBJECTIVE: We aim to develop a novel method for rare disease concept normalization by fine-tuning Llama 2, an open-source large language model (LLM), using a domain-specific corpus sourced from the Human Phenotype Ontology (HPO).
METHODS: We developed an in-house template-based script to generate two corpora for fine-tuning. The first (NAME) contains standardized HPO names, sourced from the HPO vocabularies, along with their corresponding identifiers. The second (NAME+SYN) includes HPO names and half of the concept's synonyms as well as identifiers. Subsequently, we fine-tuned Llama 2 (Llama2-7B) for each sentence set and conducted an evaluation using a range of sentence prompts and various phenotype terms.
RESULTS: When the phenotype terms for normalization were included in the fine-tuning corpora, both models demonstrated nearly perfect performance, averaging over 99% accuracy. In comparison, ChatGPT-3.5 has only ∼20% accuracy in identifying HPO IDs for phenotype terms. When single-character typos were introduced in the phenotype terms, the accuracy of NAME and NAME+SYN is 10.2% and 36.1%, respectively, but increases to 61.8% (NAME+SYN) with additional typo-specific fine-tuning. For terms sourced from HPO vocabularies as unseen synonyms, the NAME model achieved 11.2% accuracy, while the NAME+SYN model achieved 92.7% accuracy.
CONCLUSION: Our fine-tuned models demonstrate ability to normalize phenotype terms unseen in the fine-tuning corpus, including misspellings, synonyms, terms from other ontologies, and laymen's terms. Our approach provides a solution for the use of LLMs to identify named medical entities from clinical narratives, while successfully normalizing them to standard concepts in a controlled vocabulary.
Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by board-certified kinesio therapists. The objectives of the training sessions will match those of RAS.
In the event of a radiological exposure incident, such as the detonation of a radiological dispersion device (RDD) in a terrorist attack or accidental exposures to sources of ionizing radiation, it is advantageous to use multiple methods to assess the dosimetry of individuals exposed to this radiation (4). These methods should include a physical assessment of the dosimetry at the exposure site to, 1) identify the type of radiation (e.g., gamma rays, neutrons or radioisotopes), 2) evaluate the distribution of radioisotopes and/or radioactivity at the site, and 3) determine the location of exposed individuals to the source of radiation. For individuals affected by the radiological incident, the monitoring of their clinical signs and symptoms is important for determining whether acute symptoms of radiation sickness are being presented and if immediate medical intervention is required. However, it is recognized that an invaluable aid for the clinical management of exposed individuals is the use of biomarkers that can be readily obtained from the exposed individual and used for assessing dosimetry (4,9). Biomarkers that are most useful to the physician are those produced or expressed within minutes to hours following exposure. With the dosimetry provided through these early phase biomarker measurements, the physician can better assess the clinical signs that are presented by an exposed individual and better determine the need and course of treatment.
Renal transplant recipients will receive standard immunosuppressive therapy, including steroids (Methylprednisolone), rATG, Tacrolimus and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
There is no treatment on this study, it is a onetime assessment. exercisers: ≥120 minutes of vigorous-intensity aerobic exercise;There is no treatment on this study, it is a onetime assessment. non-exercisers: ≤ 30 minutes of moderate-intensity exercise per week.
Patients undergo radiation therapy 5 days a week for a total of 28 fractions. Patients also receive capecitabine PO BID on the days of radiation therapy and curcumin PO BID in weeks 1-11.5.
Tumor-associated macrophages (TAMs) originating from monocytes are crucial for cancer progression; however, the mechanism of TAM differentiation is unclear. We investigated factors involved in the differentiation of monocytes into TAMs within the tumor microenvironment of triple-negative breast cancer (TNBC). We screened 172 compounds and found that a heat shock protein 90 (HSP90) inhibitor blocked TNBC-induced monocyte-to-TAM differentiation in human monocytes THP-1. TNBC-derived conditional medium (CM) activated cell signaling pathways, including MAP kinase, AKT and STAT3, and increased the expression of TAM-related genes and proteins. These inductions were suppressed by HSP90 inhibition or by knockdown of HSP90 in TNBC. Additionally, we confirmed that TNBC secreted HSP90 extracellularly and that HSP90 itself promoted TAM differentiation. In a mouse tumor model, treatment with an HSP90 inhibitor suppressed tumor growth and reduced TAMs in the tumor microenvironment. Our findings demonstrate the role of HSP90 in TAM differentiation, suggesting HSP90 as a potential target for TNBC immunotherapy due to its regulatory role in monocyte-to-TAM differentiation.
PURPOSE: An eye make-up cosmetic composition containing a high-branched olefin polymer, behenin or behenin derivatives, and polysaccharide is provided. Therefore, the composition is not irritative to the skin and eyes, minimized in aging and improved in stability, coloring properties and long-lasting effect without agglomeration or greasiness. CONSTITUTION: An eye make-up cosmetic composition comprises 0.1 to 15.0% by weight of a high-branched olefin polymer, below 1.0% by weight of behenin or a behenin derivative and 0.1 to 5.0% by weight of polysaccharide. The olefin polymer has a molecular weight of 2,000 to 4,000, a melting point of 68 to 75deg.C and a polymerization degree of 10 to 20. The behenin or behenin derivative has a melting point of 69 to 74deg.C and a glyceryl monomer content of 1.0% by weight or less and is selected from glyceryl dibehenate, glyceryl behenate and tribehenin. The eye make-up cosmetic composition is any one of an emulsion mascara composition, a dispersion mascara composition, a dispersion eyeliner and a dispersion eye shadow.
BACKGROUND: Epigenetic scores (EpiScores), reflecting DNA methylation (DNAm)-based surrogates for complex traits, have been developed for multiple circulating proteins. EpiScores for pro-inflammatory proteins, such as C-reactive protein (DNAm CRP), are associated with brain health and cognition in adults and with inflammatory comorbidities of preterm birth in neonates. Social disadvantage can become embedded in child development through inflammation, and deprivation is overrepresented in preterm infants. We tested the hypotheses that preterm birth and socioeconomic status (SES) are associated with alterations in a set of EpiScores enriched for inflammation-associated proteins.
RESULTS: In total, 104 protein EpiScores were derived from saliva samples of 332 neonates born at gestational age (GA) 22.14 to 42.14 weeks. Saliva sampling was between 36.57 and 47.14 weeks. Forty-three (41%) EpiScores were associated with low GA at birth (standardised estimates |0.14 to 0.88|, Bonferroni-adjusted p-value < 8.3 × 10-3). These included EpiScores for chemokines, growth factors, proteins involved in neurogenesis and vascular development, cell membrane proteins and receptors, and other immune proteins. Three EpiScores were associated with SES, or the interaction between birth GA and SES: afamin, intercellular adhesion molecule 5, and hepatocyte growth factor-like protein (standardised estimates |0.06 to 0.13|, Bonferroni-adjusted p-value < 8.3 × 10-3). In a preterm subgroup (n = 217, median [range] GA 29.29 weeks [22.14 to 33.0 weeks]), SES-EpiScore associations did not remain statistically significant after adjustment for sepsis, bronchopulmonary dysplasia, necrotising enterocolitis, and histological chorioamnionitis.
CONCLUSIONS: Low birth GA is substantially associated with a set of EpiScores. The set was enriched for inflammatory proteins, providing new insights into immune dysregulation in preterm infants. SES had fewer associations with EpiScores; these tended to have small effect sizes and were not statistically significant after adjusting for inflammatory comorbidities. This suggests that inflammation is unlikely to be the primary axis through which SES becomes embedded in the development of preterm infants in the neonatal period.
PURPOSE: A composition containing venison hydrolysate having anti-oxidation effects is provided to protect DNA and effectively suppress or treat aging and various diseases. CONSTITUTION: An anti-oxidation composition contains venison hydrolysate, anti-oxidative peptide, or their mixture as an active ingredient. The anti-oxidation peptide has an amino acid sequence of sequence number 1 or 2. The anti-oxidation composition is used in the form of medicinal and pharmaceutical product, supplementary health food, cosmetic product, food or food additive. The venison hydrolysate is obtained by treating protease in pH 1.0-10.0 buffer solution, at 25-70°C for 6 to 10 hours. The buffer is phosphate buffer or glycine-HCl buffer. The anti-oxidation peptide is purified through 4 steps comprising ion exchange liquid chromatography using anion resin, high performance chromatography having C18 column, high performance chromatography having C18 for two times.
The grading of non-muscle invasive bladder cancer (NMIBC) continues to face challenges due to subjective interpretations, which affect the assessment of its severity. To address this challenge, we are developing an innovative artificial intelligence (AI) system aimed at objectively grading NMIBC. This system uses a novel convolutional neural network (CNN) architecture called the multi-scale pyramidal pretrained CNN to analyze both local and global pathology markers extracted from digital pathology images. The proposed CNN structure takes as input three levels of patches, ranging from small patches (e.g., 128 × 128  ) to the largest size patches ( 512 × 512  ). These levels are then fused by random forest (RF) to estimate the severity grade of NMIBC. The optimal patch sizes and other model hyperparameters are determined using a grid search algorithm. For each patch size, the proposed system has been trained on 32K patches (comprising 16K low-grade and 16K high-grade samples) and subsequently tested on 8K patches (consisting of 4K low-grade and 4K high-grade samples), all annotated by two pathologists. Incorporating light and efficient processing, defining new benchmarks in the application of AI to histopathology, the ShuffleNet-based AI system achieved notable metrics on the testing data, including 94.25% ± 0.70% accuracy, 94.47% ± 0.93% sensitivity, 94.03% ± 0.95% specificity, and a 94.29% ± 0.70% F1-score. These results highlight its superior performance over traditional models like ResNet-18. The proposed system's robustness in accurately grading pathology demonstrates its potential as an advanced AI tool for diagnosing human diseases in the domain of digital pathology.
PURPOSE: A pharmaceutical composition for suppressing cancer recurrence or metastasis is provided to reduce side effects and to enable effective treatment. CONSTITUTION: A pharmaceutical composition for suppressing cancer recurrence or metastasis contains 10-4000 mg of 2-deoxy-D-gluscose as an active ingredient. The pharmaceutical composition contains a biguanide-based therapeutic agent for treating diabetes or a pharmaceutically acceptable salt thereof, and 2-deoxy-D-gluscose as active ingredients. The therapeutic agent is metformin, phenformin, or buformin. The pharmaceutically acceptable salt of metformin is hydrochloride or acetate. The pharmaceutical composition is an oral formulation or a parenteral formulation. The pharmaceutical composition additionally contains an anticancer agent as an active ingredient. The cancer is colon cancer or breast cancer. [Reference numerals] (AA) Mammosphere formation; (BB) Hydrochloride of metformin; (CC) Hydrochloride of metformin + 2-DG